Current Development Projects/Franchises |
available for cooperation and licensing |
|
|
|
|
Pharmacologically active bisphosphonates for treatment of bone diseases
|
|
Lead compound:
|
CAD, first cytotoxic bisphosphonate
|
|
Status:
|
Pre-Phase I
|
|
Collaborations:
|
Henkel KGaA, Düsseldorf (GER)
University of Bremen (GER)
|
|
|
|
|
New indications for beta-agonists to treat muscle and nerve disorders
|
|
Platform:
|
New use patents
|
|
Lead compound:
|
Clenbuterol
|
|
Status:
|
Clinical phase II
|
|
Collaborations:
|
Rowett Research Institute, Aberdeen (UK)
University of Marburg (GER)
|
|
|
|
|
|
Magnetic drug targetting via Ferrofluids for diagnosis and treatment of cancer, etc.
|
|
Technology:
|
Magnetic nanoparticles carry drugs to diseased area
|
|
Status:
|
Formulation research
|
|
Collaborations:
|
Sustech, Darmstadt (GER)
University of Düsseldorf (GER)
|
|
|
|
|
|
Individualized dosage therapy with antiestrogens (cancer adjuvants)
|
|
Technology:
|
New genomics based diagnostic assay combined with new drug formulation
|
|
Status:
|
Assay development
|
|
Collaborations:
|
Epigenomics AG, Berlin (GER) / Seattle, (USA)
PromediPharm GmbH, Bensheim (GER)
|
|
|
|
|
|
Oral antisense therapy for various diseases
|
|
Technology:
|
New proprietary antisense molecules
|
|
Status:
|
Preclinical
|
|
Collaborations:
|
Oligos Etc. Inc., Portland (USA)
MCS Micro Carrier Systems GmbH, Neuss (GER)
|
|
|
|
|
|
Inhaled Antibiotics
|
|
Technology:
|
New bacterial seeking liposomal formulation
|
|
Status:
|
Preclinical
|
|
Collaborations:
|
Theralipids Inc., Montreal (CAN)
MCS Micro Carrier Systems GmbH, Neuss (GER)
|
